<DOC>
	<DOCNO>NCT01270386</DOCNO>
	<brief_summary>Apatinib tyrosin-inhibitor agent target vascular endothelial growth factor receptor ( VEGFR ) , 's anti-angiogenesis effect view preclinical test . Phase I study show drug 's toxicity manageable maximum tolerable daily dose 850 mg . The purpose study determine whether apatinib improve progression free survival compare placebo patient advance non-squamous non-small cell lung cancer fail two line chemotherapy .</brief_summary>
	<brief_title>A Study Apatinib Patients With Advanced Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>≥ 18 ≤ 70 year age Histologically cytologic confirm advanced nonsquamous nonsmall cell lung cancer . At least one measurable lesion receive radiotherapy ( large 10 mm diameter spiral CT scan ) Have fail 2 line chemotherapy include EGFRTKI . ECOG performance scale 0 1 . Life expectancy 3 month . Duration last therapy 6 week nitroso mitomycin More 4 week operation radiotherapy More 4 week cytotoxic agent tyrosine kinase inhibitor inhibitor Adequate hepatic , renal , heart , hematologic function ( hemoglobin ≥ 90g/L , platelet ≥ 80×10^9/L , neutrophil ≥ 1.5×10^9/L , total bilirubin within 1.25×the upper limit normal ( ULN ) , serum transaminase≤2.5×the ULN ( If liver metastasis , serum transaminase≤5×the ULN ) , serum creatine ≤ 1.5 x ULN , creatinine clearance rate ≥ 50ml/min , sign date informed consent.Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Squamous cell carcinoma ( include adenosquamous carcinoma , undifferentiated carcinoma ) ; small cell lung cancer ( include small cell nonsmall cell mixed lung cancer ) Pregnant breastfeed woman Intercurrence one following : hypertension , coronary artery disease , arrhythmia heart failure Any factor influence usage oral administration PT , APTT , TT , Fbg abnormal , Receiving therapy thrombolysis anticoagulation . Within 4 week first use drug , occur pulmonary hemorrhage ( ≥ CTCAE class 2 ) part ' hemorrhage ( ≥ CTCAE class 3 ) . Longterm untreated wound fracture . Within 6 month first treatment occur artery / venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism , etc . Application anticoagulant vitamin K antagonist warfarin , heparin analogue ; If prothrombin time international normalize ratio ( INR ) ≤ 1.5 , purpose prevention , use small dos warfarin ( 1mg orally , daily ) lowdose aspirin ( 80mg 100mg daily ) allow . Abuse alcohol drug Less 4 week last clinical trial Treatment VEGFR , PDGFR , sSRCTKI . History second malignancy within 3 year except cure basal cell carcinoma skin carcinoma insitu uterine cervix .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>apatinib</keyword>
	<keyword>phase II</keyword>
	<keyword>lung</keyword>
	<keyword>cancer</keyword>
</DOC>